View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Analysis
June 10, 2021updated 02 Jul 2021 11:00am

Is the pharma sector seeing the beginnings of an AI investment boom?

AI deals, jobs and patents have been booming in the last few years. But is the pharma sector keeping up?

By Chris Lo

The pharma industry is seeing an increase in artificial intelligence (AI) investment across several key metrics, according to an analysis of GlobalData data.

Free Report
img

How attractive are current investment opportunities in Europe?

Europe has been identified as one of the most favorable regions for investors, seeing high investment activity in the past year. Most of these investments have been through Debt Offering, valued at close to $700 billion. The region has provided attractive investments in a diverse set of companies. Companies who tend to major themes such Digital Media, Cloud, Artificial Intelligence, E-commerce, and Big Data are recording the highest number of deals, with Digital Media recording close to 2,000 deals. However, GlobalData’s whitepaper offers a full view of the market, analyzing less successful or attractive points of investment as well, examining statistics on Equity Offering investments and PE/VC deals. Understand how government agencies for economies around the world use GlobalData Explorer to:  
  • Track the M&A and Capital Raising volumes into their target market
  • Identify the top sectors in the target market attracting the investments
  • For any investment segment, identify the top Investors inside and outside the target economy that are already investing in the Segment
  • Assess and showcase the growth potential for various Industries in the target economy
Don’t miss out on key market insights that can help optimize your next investment – read the report now.
by GlobalData
Enter your details here to receive your free Report.

AI is gaining an increasing presence across multiple sectors, with top companies completing more AI deals, hiring for more AI roles and mentioning it more frequently in company reports at the start of 2021.

GlobalData’s thematic approach to sector activity seeks to group key company information on hiring, deals, patents and more by topic to see which companies are best placed to weather the disruptions coming to their industries.

These themes, of which AI is one, are best thought of as “any issue that keeps a CEO awake at night”, and by tracking them it becomes possible to ascertain which companies are leading the way on specific issues and which are dragging their heels.

Free White Paper

By
Enter your details to receive the free paper:

According to this method, Novartis, GlaxoSmithKline, Merck & Co are classed as dominant players in AI in the sector, with an additional 19 companies classified as leaders. 10 companies are considered to be vulnerable due to a lack of investment in AI.

One area in which there has been some increase in AI investment among pharma companies is in the number of deals. GlobalData show that there were 44 AI deals in pharma in the first quarter of 2019. By the first quarter of 2021, that number was 85.

Hiring patterns within the pharma sector as a whole are pointing towards an increase in the level of attention being shown to AI-related roles. There was a monthly average of 955 actively advertised-for open AI roles within the industry in April this year, up from a monthly average of 712 in December 2020.

It is also apparent from an analysis of keyword mentions in financial filings that AI is occupying the minds of pharma companies to an increasing extent.

There have been 1,346 mentions of AI across the filings of the biggest pharma companies so far in 2021, equating to 12.1% of all tech theme mentions. This figure represents an increase compared to 2016, when AI represented 4.8% of the tech theme mentions in company filings.

AI is increasingly fueling innovation in the pharma sector, particularly in the past six years. There were, on average, 16 pharma patents related to AI granted each year from 2000 to 2014. That figure has risen to an average of 49 patents since then, reaching 75 in 2020.

Related Companies

Free Report
img

How attractive are current investment opportunities in Europe?

Europe has been identified as one of the most favorable regions for investors, seeing high investment activity in the past year. Most of these investments have been through Debt Offering, valued at close to $700 billion. The region has provided attractive investments in a diverse set of companies. Companies who tend to major themes such Digital Media, Cloud, Artificial Intelligence, E-commerce, and Big Data are recording the highest number of deals, with Digital Media recording close to 2,000 deals. However, GlobalData’s whitepaper offers a full view of the market, analyzing less successful or attractive points of investment as well, examining statistics on Equity Offering investments and PE/VC deals. Understand how government agencies for economies around the world use GlobalData Explorer to:  
  • Track the M&A and Capital Raising volumes into their target market
  • Identify the top sectors in the target market attracting the investments
  • For any investment segment, identify the top Investors inside and outside the target economy that are already investing in the Segment
  • Assess and showcase the growth potential for various Industries in the target economy
Don’t miss out on key market insights that can help optimize your next investment – read the report now.
by GlobalData
Enter your details here to receive your free Report.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology